A
Alcista
Alcista · 25%KMDA
$7.88
Precio del escenario
$8.050
+0.112 (+1.39%)Al cierre
Loading chart…
- Máximo
- 8.090
- Apertura
- 7.930
- Precio medio ponderado por volumen
- 7.93
- Volumen
- 73.85K
- Capitalización
- 289.98M
- Mínimo
- 7.660
- Importe
- 585.84K
- EV/EBITDA, TTM
- 3.21
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Análisis de IA of Kamada Ltd (KMDA)
ComprarKamada Ltd appears to be a good buy right now due to its recent FDA approval for a new laboratory, which enhances its operational capabilities and positions it well in the growing rabies immunoglobulin market. The current price of $7.77 is below the Fibonacci R1 level of $7.94, suggesting potential upside. Additionally, the company has shown a strong gross margin of 40.91% in Q2 2026, indicating solid profitability. However, a key risk is the recent Q1 earnings miss, where EPS was $0.07, falling short of expectations by $0.05, which could impact investor sentiment in the short term.
Recomendaciones de analistas (1)
+73.91% de potencial alcista
Comprar
1 Comprar
0 Mantener
0 Vender
Actual: 8.05
Mínimo
13.00
Promedio
14.00
Máximo
15.00
H.C. Wainwright
Comprar
$13
2025-12-09
H.C. Wainwright
2025-12-09
Precio objetivo
$13
Comprar
Benchmark
Compra fuerte
$15
2025-03-21
Benchmark
2025-03-21
Precio objetivo
$15
Compra fuerte
HC Wainwright & Co.
Compra fuerte
$11
2025-03-06
HC Wainwright & Co.
2025-03-06
Precio objetivo
$11
Compra fuerte
HC Wainwright & Co.
Compra fuerte
$11
2025-01-10
HC Wainwright & Co.
2025-01-10
Precio objetivo
$11
Compra fuerte
HC Wainwright & Co.
Compra fuerte
$11
2024-11-14
HC Wainwright & Co.
2024-11-14
Precio objetivo
$11
Compra fuerte
Métricas de valoración
El PER previsto actual de Kamada Ltd (KMDA) es 16.53, frente a su media de 5 años de 6.64.
Escenarios de precio de Alphio AI para KMDA
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con KMDA en cartera
Cronología de eventos
Noticias
1.010-19NewsfilterKamada CEO to Attend Investor Conferences in November
7.509-17NASDAQ.COMKamada Addresses Surge in U.S. Rabies Demand
- 8.008-17Newsfilter
Kamada Declares $0.17 Cash Dividend Per Share
- 5.008-12Newsfilter
Kamada CFO Chaime Orlev to Depart for New Opportunities
- 9.508-12Newsfilter
Kamada Reports Record $100.2 Million Revenue in First Half of 2026
Preguntas frecuentes sobre KMDA, respondidas por Alphio AI
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Kamada Ltd appears to be a good buy right now due to its recent FDA approval for a new laboratory, which enhances its operational capabilities and positions it well in the growing rabies immunoglobulin market. The current price of $7.77 is below the Fibonacci R1 level of $7.94, suggesting potential upside. Additionally, the company has shown a strong gross margin of 40.91% in Q2 2026, indicating solid profitability. However, a key risk is the recent Q1 earnings miss, where EPS was $0.07, falling short of expectations by $0.05, which could impact investor sentiment in the short term.
1 analysts cover KMDA: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 14.00.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.